Dipanjan Basu1, Cláudia M Salgado1, Bruce S Bauer1, Donald Johnson1, Veronica Rundell1, Marina Nikiforova1, Yasmin Khakoo1, Lorelei J Gunwaldt1, Ashok Panigrahy1, Miguel Reyes-Múgica1. 1. Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.).
Abstract
BACKGROUND: Neurocutaneous melanocytosis (NCM) is characterized by clonal nevomelanocytic proliferations in the CNS and skin. Given the scarcity of effective therapeutic targets, testing new drugs requires a reliable and reproducible in vitro cellular model of the disease. METHODS: We generated nevomelanocytic spheroids in vitro from lesions of the spinal cord, brain, and skin from 4 NCM patients. Nevomelanocytic cells were grown as monolayers or spheroids and their growth characteristics were evaluated. Cultured cell identity was confirmed by demonstration of the same NRAS mutation found in the original lesions and by immunophenotyping. Nevomelanocytic spheroids were treated with inhibitors of specific mediators of the NRAS signaling pathway (vemurafenib, MEK162, GDC0941, and GSK2126458). Drug sensitivity and cell viability were assessed. RESULTS: Cultured cells were growth-factor dependent, grew as spheroids on Geltrex matrix, and maintained their clonogenicity in vitro over passages. Skin-derived cells formed more colonies than CNS-derived cells. Inhibitors of specific mediators of the NRAS signaling pathway reduced viability of NRAS mutated cells. The highest effect was obtained with GSK2126458, showing a viability reduction below 50%. CONCLUSIONS: NRAS mutated cells derived from clinical NCM samples are capable of continuous growth as spheroid colonies in vitro and retain their genetic identity. Drugs targeting the NRAS signaling pathway reduce in vitro viability of NCM cells. NCM lesional spheroids represent a new and reliable experimental model of NCM for use in drug testing and mechanistic studies.
BACKGROUND:Neurocutaneous melanocytosis (NCM) is characterized by clonal nevomelanocytic proliferations in the CNS and skin. Given the scarcity of effective therapeutic targets, testing new drugs requires a reliable and reproducible in vitro cellular model of the disease. METHODS: We generated nevomelanocytic spheroids in vitro from lesions of the spinal cord, brain, and skin from 4 NCM patients. Nevomelanocytic cells were grown as monolayers or spheroids and their growth characteristics were evaluated. Cultured cell identity was confirmed by demonstration of the same NRAS mutation found in the original lesions and by immunophenotyping. Nevomelanocytic spheroids were treated with inhibitors of specific mediators of the NRAS signaling pathway (vemurafenib, MEK162, GDC0941, and GSK2126458). Drug sensitivity and cell viability were assessed. RESULTS: Cultured cells were growth-factor dependent, grew as spheroids on Geltrex matrix, and maintained their clonogenicity in vitro over passages. Skin-derived cells formed more colonies than CNS-derived cells. Inhibitors of specific mediators of the NRAS signaling pathway reduced viability of NRAS mutated cells. The highest effect was obtained with GSK2126458, showing a viability reduction below 50%. CONCLUSIONS:NRAS mutated cells derived from clinical NCM samples are capable of continuous growth as spheroid colonies in vitro and retain their genetic identity. Drugs targeting the NRAS signaling pathway reduce in vitro viability of NCM cells. NCM lesional spheroids represent a new and reliable experimental model of NCM for use in drug testing and mechanistic studies.
Authors: Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran Journal: Neuro Oncol Date: 2014-11-12 Impact factor: 12.300
Authors: Lawrence N Kwong; James C Costello; Huiyun Liu; Shan Jiang; Timothy L Helms; Aliete E Langsdorf; David Jakubosky; Giannicola Genovese; Florian L Muller; Joseph H Jeong; Ryan P Bender; Gerald C Chu; Keith T Flaherty; Jennifer A Wargo; James J Collins; Lynda Chin Journal: Nat Med Date: 2012-09-16 Impact factor: 53.440
Authors: Alia Albawardi; Muna Al Ayyan; Mohamed Al Bashir; Abdul-Kader Souid; Saeeda Almarzooqi Journal: Cancer Cell Int Date: 2014-09-24 Impact factor: 5.722
Authors: Dipanjan Basu; Cláudia M Salgado; Bruce Bauer; Yasmin Khakoo; Janki R Patel; Ryan M Hoehl; Dominique M Bertolini; Joie Zabec; Morgan R Brzozowski; Miguel Reyes-Múgica Journal: Cancer Genomics Proteomics Date: 2018 Jul-Aug Impact factor: 4.069